Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
- 27 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 26 (5), 720-731
- https://doi.org/10.1038/s41591-020-0827-2
Abstract
Recurrent medulloblastoma and ependymoma are universally lethal, with no approved targeted therapies and few candidates presently under clinical evaluation. Nearly all recurrent medulloblastomas and posterior fossa group A (PFA) ependymomas are located adjacent to and bathed by the cerebrospinal fluid, presenting an opportunity for locoregional therapy, bypassing the blood–brain barrier. We identify three cell-surface targets, EPHA2, HER2 and interleukin 13 receptor α2, expressed on medulloblastomas and ependymomas, but not expressed in the normal developing brain. We validate intrathecal delivery of EPHA2, HER2 and interleukin 13 receptor α2 chimeric antigen receptor T cells as an effective treatment for primary, metastatic and recurrent group 3 medulloblastoma and PFA ependymoma xenografts in mouse models. Finally, we demonstrate that administration of these chimeric antigen receptor T cells into the cerebrospinal fluid, alone or in combination with azacytidine, is a highly effective therapy for multiple metastatic mouse models of group 3 medulloblastoma and PFA ependymoma, thereby providing a rationale for clinical trials of these approaches in humans.Keywords
Funding Information
- EIF | Stand Up To Cancer (SU2C-AACR-DT1113, SU2C-AACR-DT-19-15, SU2C-AACR-DT1113)
- DH | NIHR | Programme Development Grants (R01CA148699, R01CA159859, U54 CA232568-01)
- Stand Up To Cancer - St Baldrick’s Foundation Paediatric Immunotherapy Dream Team.
This publication has 57 references indexed in Scilit:
- Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serumBlood, 2012
- Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)Blood, 2012
- Clonal selection drives genetic divergence of metastatic medulloblastomaNature, 2012
- Molecular subgroups of medulloblastoma: the current consensusActa Neuropathologica, 2011
- Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa EpendymomaCancer Cell, 2011
- Challenging issues in pediatric oncologyNature Reviews Clinical Oncology, 2011
- Equitoxic Doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine Induce Diverse Immediate and Overlapping Heritable Changes in the TranscriptomePLOS ONE, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabineInternational Journal of Cancer, 2008
- Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.JCI Insight, 1993